Photodegradation of some quinolones used as antimicrobial therapeutics by Tiefenbacher, E. M. et al.
Photodegradation of Some Quinolones Used as Antimicrobial Therapeutics 
EVA-MARIA TIEFENBACHER', EKKEHARD HAEN', BERNHARD PRZYBILLAS, AND HERMANN Kmz' 
Received March 5, 1992, from the Walther-Straub Institute of Pharmacology and Toxicology, Ludwig-Maximilians-University, 
Nussbaumstr. 26, 0-80336 Munich, Germany, and #Department of Dermatology, Ludwig-Maximilians-University, 
Frauenlobstr. 9- 11, 0-80337 Munich, Germany. Accepted for publication October 25. 1993". 
Abstract 0 The photostability of the fluoroquinolones ciprofloxacin 
(CPX), ofloxacin (OFX), and fleroxacin (FLX) toward ultraviolet irradiation 
(UVA) and room light was investigated in dilute aqueous solutions. A 
series of photoproducts was observed by high-performance liquid 
chromatography (HPLC) for all three drugs. As little as 1 h of exposure 
to room light was enough for the formation of detectable amounts of 
CPX photoproducts. The major CPX photoproduct was characterized 
as a dimer by liquid secondary ion mass spectrometry, but its structure 
was not determined. Since irradiation of CPX results (as cited in ref/ 
11) in a loss of antibacterial activity and since all substances, parent 
drugs as well as their photoproducts, are potential candidates for 
undesired drug effects, quinolone drugs should be strictly protected 
from all light during storage and administration. 
Introduction 
The 6-fluoroquinolones ciprofloxacin, ofloxacin, and fleroxacin 
represent a class of synthetic antimicrobial agents with a broad 
range of activity against Gram-negative and Gram-positive 
organisms (Figure 1). The drugs are used for the treatment of 
severe infections of different organs.' Various side effects have 
been observed due to therapy with these compounds such as 
effects on the central nervous system and the gastrointestinal 
tract as well as photosensitivity reactions of the skin.2 Fluoro- 
quinolones absorb radiation energy in the ultraviolet range of 
the electromagnetic spectrum3 (Figure 2). Some of these 
substances have been found to exert phototoxic or photoallergic 
effects in vivo or in vitr0.e Exact mechanisms of these reactions 
are unknown so far. They could be induced by the substances 
themselves or by derivatives formed as a consequence of UV 
irradiation.7-10 
Ferguson et al.11 observed a loss of antibacterial activity of 
ciprofloxacin after UV exposure, suggesting photodegradation 
of the compound. The photodegradation itself has not yet been 
documented, as well as no information has been so far provided 
on the nature of the photoproducts. For some fluoroquinolones, 
however, metabolites have been identified with reduced anti- 
bacterial activity1214 (Figure 3). 
We assessed the formation of photoproducts after exposure 
of the fluoroquinolones ciprofloxacin, ofloxacin, and fleroxacin 
to UVA or natural/artificiallight (room light). CPX metabolites 
were available for matters of comparison. 
Materials and Methods 
Chemicals. Ciprofloxacin and four of its metabolites were kindly 
supplied by Bayer AG (Leverkusen/FRG). Specifications were as 
follows: CPX (Bay 0 9867.HCl-Hz0,98.3 % purity); metabolite M1 (Bay 
R 3964eHC1,96% purity); metaboliteM2 (Bays 9435-NH3,90.3% purity); 
metabolite M3 (Bay Q 3542,99% purity); metabolite M4 (Bay P 9357, 
99% purity). For some experiments, ciprofloxacin was used asCiprobay 
infusion concentrate (Bayer AG/FRG). OFX was kindly supplied by 
Hoechst AG (Frankfurt/FRG), FLX by Hoffmann-La Roche AG 
(Grenzach-Whylen/FRG). All reagenta were of analytical grade. Meth- 
@ Abstract published in Advance ACS Abstracts, January 15, 1994. 
Flgure 1-Molecular structures of ciprofloxacin (CPX), ofloxacin (OFX), 
and fleroxacin (FLX). 
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Flgure 2-UV absorption spectra of ciprofloxacin (A), ofloxacin (B), and 
fleroxacin (C) (maxima: ciprofloxacin, 275 nm; ofloxacin, 286 nm; 
fleroxacin, 278 nm; drug concentration: mol/L, UV/vis recording 
spectrophotometer: UV-265 FW, ShimadzulJapan). 
anol, tetrahydrofuran, disodium hydrogen phosphate, and citric acid 
were obtained from Merck (Darmstadt/FRG), tetrabutylammonium 
hydrogen sulfate from Fluka Chemie AG (Buchs/Switzerland). Water 
was demineralized, double distilled, and filtered on a Milli-Q filter system 
(Millipore Corp., Bedfort, MA). 
Sample Preparation and Irradiation-CPX, OFX, FLX, and the 
CPX metabolites were diluted.at a concentration of 1P mol/L in double- 
distilled water with addition of 1.0 mL of 0.01 N NaOH per 100.0 mL 
(pH,. = 5.4, pHof. = 6.3, p H h  = 6.3). UVA irradiation of the solutions 
was performed with a high-intensity UVA source emitting in the range 
of 320-460 nm with a maximum a t  about 375 nm (UVASUN 5000, 
Mutzhas, Munich/FRG). Irradiance at  a distance of 40 cm was 37 mW/ 
cm2 (UVA dose, 100 J/cm2; irradiation time, 33 min). During this 
procedure temperature increased from 20 "C to 37 "C. Samples covered 
by aluminium foil were used as controls. Further experiments were 
performed at  4 "C and a t  constant 20 "C (in water bath). After irradiation 
all samples were immediately protected from light by aluminium foil. 
UVA dose was measured by an integrating instrument (Centra-UV 
dosimeter, Osram, Munich/FRG). 
Exposure to natural/artificial light (room light) was studied with 
Ciprobay infusion concentrate. The concentrate was diluted to 10-6 
moVL in double-distilled water, filled in transparent glass bottles, and 
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Figure 3-Molecular structures of ciprofioxacin (CPX) and its metabolites 
M1-M4. Mi ,  desethylenciprofloxacin; M2, sulfociprofloxacin; M3, oxo- 
ciprofloxacin; M4, formylciprofloxacin. 
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Figure 4-HPLC chromatogram of ciprofloxacin mollL) without (A) 
and after (6) irradiation with 100 Jlcm2 UVA (absorbance at 275 nm; 
mobile phase: phosphate buffer pH 3.O/THF/methanol(79.2:0.8:20.0 vol 
%), 2.0 mL/L H3P04, 2.0 g/L TBA; column: BDS-Hypersil CI8, 5 pm, 150 
X 4.6 mm; flow: 1.0 mL/min; injection volume: 20 pL). 
placed on a desk in front of a window for 10-h exposure to normal day 
light. Irradiation was continued during the night with artificial light 
(desklamp, 75-W bulb, distance: 40 cm). After 1,2,3,4,12,24,48, and 
96 h, samples were drawn and protected by aluminum foil until 
chromatography was performed. 
Table 1-HPLC Retention limes of Ciprotioxacin, Its 
Metabolites M 1 4 4 ,  and Its Photoproducts Puv Formed under 
Irradiation with 100 J/cmZ UVA (min; t f SD, n = 5) 
Ciprofloxacin Metabolites Photoproducts 
~ 
Puvl: 1.82 f 0.2 
Puv3: 2.74 f 0.3 
Puv4: 3.12 f 0.4 
Puv5: 3.70 f 0.4 
Puv6: 3.86 f 0.2 
P"v2: 2.1 1 f 0.2 
M2: 4.01 f 0.2 
M1: 4.98 f 0.4 Puv7: 4.95 f 0.2 
Puv8: 5.89 f 0.3 
Ptnt9: 8.67 f 0.4 M3: 6.67 f 0.5 
5.83 f 0.1 
puvio: 14.55 f 0.7 
M4: 18.59 f 0.9 Puvl l :  18.24 f 0.3 
Puvl2: 22.41 f 0.7 
High-Performance Liquid Chromatography (HPLC)-Analytical 
Chromatography-Maxima of UV absorption of CPX, OFX, and FLX 
were determined by an UV-visible recording spectrophotometer (UV- 
265 FW, Shimadzu/Japan, Figure 2). The drug concentration was 106 
mol/L. Analytical HPLC analysis was performed by a modification of 
the procedure published by Scholl et a1.15 Reversed-phase columns (BDS- 
Hypersil Cia, 5 pm, 150 X 4.6 mm, ODs-Hypersil, 3 pm, 125 X 4.6 mm, 
Bischof GmbH, Leonberg/FRG) were connected with a constant flow 
pump (Model 300 B, Gynkotek GmbH, Munich/FRG) and a variable- 
wavelength spectrophotometer (Model SP-GV, Gynkotek). The mobile 
phase consisted of 0.67 mol/L phosphate buffer (pH 3.0)/methanol/ 
tetrahydrofuran (79.2 vol % /20.0 vol % /0.8 vol % ) with addition of 2.0 
g/L tetrabutylammonium hydrogen sulfate (TBA) and 2.0 ml/L phos- 
phoric acid (85%). The solution was passed over a membrane filter 
(pore size 0.45 pm) and sonificated for 60 s with a sonorex RK 100 
ultrasonic homogenizer (Brandelin GmbH, Berlin/FRG) before chroma- 
tography. The flow was 1.0 mL/min, the injection volume 20 pL. The 
substances were detected at  275 (CPX), 286 (OFX), and 278 nm (FLX). 
Preparative Chromatography-The chromatograph consisted of 
the following modules: a pump (Model 300 B, Gynkotek GmbH, Munich/ 
FRG), an automatic sampler (Model GINA, Gynkotek GmbH), a 
preparative reversed-phase column (HIPAK CIS, 5 pm, 250 X 20 mm, 
Bischof GmbH, Leonberg/FRG), and a variable-wavelength detector 
(Model SP-GV, Gynkotek GmbH). The solvent system was a mixture 
of 59.2 % double-distilled water, 40.0 % methanol, and 0.8% tetrahydro- 
furan with addition of 50.0 mL/L formic acid. The flow was adjusted 
to 9 mL/min. The injection volume was 100 pL, and the separation was 
monitored at  275 nm. 
Mass Spectrometry-The liquid secundary ion mass spectrometry 
(LSI-MS) was performed with a HSQ 30 mass spectrometer (Finnigan 
MAT, Bremen/FRG). The probe temperature was 20 O C ,  the ionization 
energy 70 eV. A cesium ion beam was used (acceleration voltage, 7 kV; 
100-pA ion beam). The matrix consisted of glycerol. Spectrometry 
was performed in W. Schafer's laboratory (Max-Planck-Institute, 
Martinsried/FRG). 
Results 
UVA-Nonirradiated CPX was detected at  a retention time 
of 5.83 f 0.1 min (f f SD, n = 5). CPX metabolites Ml-M4 
were found between 4.01 f 0.2 and 18.59 f 0.9 min (X f SD, n 
= 5, Table 1). After UVA irradiation, the chromatograms of 
CPX solutions exhibited at least 12 well-defined peaks (Pwl- 
Puvl2) detected between 1.82 * 0.2 and 22.41 f 0.7 min (Figure 
4). Nonirradiated OFX was detected at 6.38 f 0.2 min (f f SD, 
n = 3). Following UVA irradiation, there were at least seven 
degradation products with retention times between 2.88 f 0.3 
and 15.2 f 0.5 rnin (Figure 5). Nonirradiated FLX was detected 
at 4.94 f 0.3 min (2 f SD, n = 3). After UVA exposure at  least 
eight peaks occurred at  5.09 f 0.2 to 13.41 f 0.3 min (Figure 6). 
Identical chromatograms were obtained after irradiations 
performed a t  constant temperatures of 4 OC or 20 OC. No 
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Table 2-Concentratlons of Clprofloxacln Photoproducts PL 
Formed under Irradiation with Natural/Artlflclal Llght (Peak Area 
In % of Peak Area of Parent Drug, R,: Retentlon Tlme) 
Exposure Time 
PL R,(min) l h  2 h  3 h  4h  12h 24h 48h 96h 
1 
A 
PLl: 1.93 0.1 0.1 0.2 0.2 0.2 0.3 0.3 
P L ~ :  2.36 0.1 0.1 0.1 0.1 0.2 0.2 0.6 
P L ~ :  3.22 0.1 0.1 0.2 0.2 0.4 0.4 0.8 
P L ~ :  3.97 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.4 
P L ~ :  5.03 0.2 0.4 0.5 0.7 1.2 1.5 2.5 6.3 
P,7: 8.97 0.1 0.1 0.2 0.4 
Total 0.3 0.8 0.9 1.3 1.9 2.6 3.7 8.8 
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Flgure 5-HPLC chromatogram of ofloxacin mol/L) without (A) and 
after (B) irradiation with 100 J/cm2 UVA (absorbance at 286 nm, mobile 
phase: phosphate buffer pH S.O/THF/methanol (79.2:0.8:20.0 vol %). 
2.0 mL/L H3P04, 2.0 g/L TEA; column: ODs-Hypersil CIS, 3 pm, 125 X 
4.6 mm; flow: 1.0 mL/min; injection volume: 20 pL). 
degradation of the substances was observed in control samples 
(irradiated under cover with aluminum foil). 
Natural/Artificial Light-Under irradiation of CPX sol- 
utions with natural/artificial ambient light the peak of the parent 
substance (PL~)  decreased continuously. Concomitantly, new 
peaks (PL~-PL~, P L ~ )  appeared in increasing concentrations with 
retention times between 1.93 f 0.1 and 8.97 f 0.2 min (a f SD, 
n = 5, Figure 7, Table 2). The most prominent peak was detected 
at 5.03 f 0.1 min, similar to the retention time of P U V ~  at  4.95 
f 0.2 min (Table 1). 
Chromatographic Puri ty  of CPX-Concentrations of CPX 
photoproducts were calculated from peak areas. The sum of 
peak areas formed in Ciprobay infusion concentrate after UVA 
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Flgure 6-HPLC chromatogram of fleroxacin mol/L) without (A) and 
after (B) irradiation with 100 J/cm2 UVA (absorbance at 278 nm; mobile 
phase: phosphate buffer pH S.O/THF/methanol (79.2:0.8:20.0 vol %), 
2.0 g/L H3P04, 2.0 mL/L TBA; column: ODs-Hypersil CI8, 3 pm, 125 X 
4.6 mm; flow: 1.0 mL/min; injection volume: 20 pL). 
exposure with 100 J/cm2 UVA amounted to 17.0 f 1.8% of the 
parent drug, after 96-h exposure to room light to 8.8 f 1.4% 
(Table 2). 
LSI Mass Spec t ra  of CPX Photoproducts Puv7 and  
Puv8-The LSI mass spectra of CPX and photoproduct Pw8 
with their typical fragmentation pathway are given in Figure 8. 
The characteristic peaks in the MS of CPX are in complete 
agreement with those of Puv8: m/z 332 (M + H), 290 (M - 
C2H4N), 246 (M - COa- CZH~N), and 57 (C3HeN). The LSI-MS 
of CPX photoproduct P U V ~  is demonstrated in Figure 9. The 
characteristic peaks are displayed at  m/z 703 (M + K), 683 
(M-HzO), and 665 (M - M). 
Discussion and Conclusions 
All quinolones investigated degraded under exposure to UVA. 
Ciprofloxacin exposure to natural/artificial ambient light which 
always occurs when the drug is handled also leads to the formation 
of numerous photoproducts. These degradations were temper- 
ature independent, which is strong evidence that they are actually 
caused by irradiation. 
CPX photoproduct Pw8 is detected in the HPLC chromato- 
gramm at  the same retention time as nonirradiated ciprofloxacin, 
suggesting their structural identity. This is confirmed by mass 
spectrometry of the compounds: both spectra exhibit exactly 
the same fragmentation pathway. Consequently ''Pw8" does 
not represent a light-induced degradation product but parent 
ciprofloxacin which has not yet been decomposed under UVA 
influence. 
The HPLC retention times of CPX photoproducts Puv7 and 
metabolite M1 are also very similar. The published MS spectrum 
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Figure 7-HPLC chromatograms of ciprofloxacin under irradiation with naturallartificial light (room light) after 1 h (A), 2 h (B), 3 h (C), 4 h (D), 12 h 
(E ) ,  24 h (F), 48 h (G), and 96 h (H) (nonirradiated ciprofloxacin, Figure 4). 
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Figure 8-LSI-MS of ciprofloxacin (CPX) and CPX photoproduct Puv6. 
of M1,12 however, shows marked differences to the spectrum of 
Puv7 obtained in this study. In the MS spectrum of P"$, the 
characteristic ions are displayed at  very high molecular weights, 
suggesting they might result from an UVA-induced CPX 
dimerization. Indeed, such a reaction could be expected from 
photochemical aspect: after UVA absorption the electronically 
excited states-likely in form of free radicals-become stabilized 
by bond reorganization of two radicals leading to CPX dimers. 
Figure 9-LSI-MS of CPX photoproduct Puv7. 
Whether this hypothesis is correct will be shown by nuclear 
magnetic resonance spectrometry which is currently under 
investigation in our laboratory. 
A reduction of antibacterial activity of ciprofloxacin has been 
reported after UVA exposure. Ferguson et a1.l1 suggested this 
to be the result of photodegradation of the substance. The results 
of this study demonstrate a considerable decrease of the 
concentration of ciprofloxacin under UVA exposure. Further- 
more, a reduced antimicrobial activity has been reported for the 
metabolites of ciprofloxacin,16 suggesting that the photoproducts, 
too, will exhibit less antibacterial activity than the parent 
substance. Both mechanisms support the hypothesis that 
photodegradation of ciprofloxacin is responsible for the loss of 
antibacterial activity following UVA irradiation. 
The extent of quinolone degradation depends on radiation 
dose. Photoproducts formed in ciprofloxacin infusion concen- 
trate after exposure to 100 J/cm2 UVA amount to 17.0 f 1.8% 
of the parent drug. After 4 h of exposure to room light, 1.3 f 
0.4% and, after 96 h, 8.8 i 1.4% of the parent drug are degraded, 
numerous new substances have been formed (Table 2). 
Photoproducts formed outside the organism under natural 
light conditions may be not only relevant to the loss of 
antibacterial activity, but also to the occurrence of side effe~ts,*~-lg 
phototoxic as well as others. Further work is necessary to 
486 /Journal of Pharmaceutical Sciences 
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evaluate the toxic potential of the fluoroquinolone photoproducts. 
To avoid progressive photodegradation, quinolones should be 
protected from natural and artificial light. For example they 
should be stored in amber glass bottles. Such precautions are 
easy to perform. They will minimize the loss of therapeutic 
activity as well as potentially increase the tolerance of the drugs, 
thereby optimizing the therapeutic potential of these valuable 
antibacterial agents. 
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